SCM
IOBT

Stonepine Capital Management’s IO Biotech IOBT Stock Holding History

Stonepine Capital Management’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-156,167
Closed -$270K – 27
2024
Q1 		$270K Sell
156,167
-1,509,870
-91% -$2.62M 0.21% 19
2023
Q4 		$3.13M Sell
1,666,037
-309,271
-16% -$369K 1.35% 9
2023
Q3 		$2.79M Buy
+1,975,308
New +$3.47M 0.93% 18

Other funds holding IOBT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Stonepine Capital Management's IOBT Position: Q2 2024 in Review

Stonepine Capital Management sold out of IO Biotech (IOBT) in Q2 2024, closing a stake of 156,167 shares — an estimated $270K sold.

Stonepine Capital Management first reported a position in IOBT in Q3 2023 and held it in 3 quarters. The position peaked at $3.13M in Q4 2023. 20 funds tracked by Wall St. Rank hold IOBT as of Q2 2024.

  • Stonepine Capital Management reported no remaining IO Biotech position as of Q2 2024 after selling out during the quarter.
  • Stonepine Capital Management sold 156,167 IO Biotech shares in Q2 2024, an estimated $270K.
  • Stonepine Capital Management first reported a position in IO Biotech in Q3 2023 and held it in 3 quarters.
  • Stonepine Capital Management's IO Biotech position peaked at $3.13M in Q4 2023.
  • 20 funds tracked by Wall St. Rank held IO Biotech as of Q2 2024.

Based on Stonepine Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.